March 16, 2022
RFA-HL-23-006 - Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
NOT-HL-22-008 - Notice of Correction to Eligibility Information in RFA-HL-23-006, "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)"
NOT-HL-22-009 - Notice of Correction to Specific Areas of Research Interest of Participating Institutes and Centers In RFA-HL-23-006, "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)"
National Heart, Lung, and Blood Institute (NHLBI)
On January 18, 2022, the National Heart, Lung and Blood Institute (NHLBI) issued Funding Opportunity Announcement (FOA) RFA-HL-23-006, "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)". The purpose of this Notice is to inform the applicant community of corrections to Eligibility for the Resident-Investigatorsand Application Types permitted in response to this funding opportunity.
The following sections of RFA-HL-23-006, Part 2. Full Text of Announcement have been modified (changes shown in bold italics):
Correction 1. Section II. Award Information
Currently Reads:
Application Types Allowed
New
Resubmission
Modified to Read (changes in bold italics):
Application Types Allowed
New
Resubmission
Renewal
Correction 2. Section V. Application Review Information
Currently Reads:
1. Criteria
Renewals
Not Applicable
Modified to Read (changes in bold italics):
1. Criteria
Renewals
For Renewals, the committee will consider the progress made in the last funding period.
Correction 3. Section III. Eligibility Information
Currently Reads:
3. Additional Information on Eligibility
Resident-Investigators
For the purposes of this Funding Opportunity, Resident-Investigators include individuals with health professional doctoral degrees (e.g., MD, DO, MBBS, DDS, DMD, OD, ND, DVM; with or without a research doctorate) engaged in graduate medical education consisting of advanced clinical training (herein referred to as “residency”).
Modified to Read (changes in bold italics):
3. Additional Information on Eligibility
Resident-Investigators
For the purposes of this Funding Opportunity, Resident-Investigators include individuals with health professional doctoral degrees (e.g., MD, DO, MBBS, DDS, DMD, OD, ND, DVM; with or without a research doctorate) engaged in graduate medical education consisting of advanced clinical training (herein referred to as “residency”).
Resident-Investigators are required to have a full-time appointment at the applicant institution, and to commit a minimum of 9.6 person-months (80% effort to research over 12 months) of the residency.
By the time of the appointment to the program, the individual must be a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence (i.e. possess a currently valid Permanent Resident Care USCIS Form 1-551, or other legal verification of such status.
All other aspects of the FOA remain unchanged.
Scientific/Research Contact
David Schopfer, M.D.
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-402-3833
Email: [email protected]
and Human Services (HHS)
